check_circleStudy Completed

Uterine fibroids, Endometriosis

Pharmacokinetics and safety of vilaprisan in renal impairment

Trial purpose

The purpose of the study is to evaluate the pharmacokinetics of vilaprisan in subjects with moderate to severe renal impairment compared with matched subjects with normal renal function.

Key Participants Requirements

Sex

All

Age

18 - 79 Years

Trial summary

Enrollment Goal
26
Trial Dates
February 2018 - February 2019
Phase
Phase 1
Could I Receive a placebo
No
Products
Vilaprisan (BAY1002670)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Completed
Clinical Pharmacology of Miami, Inc.Miami, 33014, United States
Completed
Orlando Clinical Research CenterOrlando, 32809, United States

Primary Outcome

  • Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of BAY1002670
    Area under the concentration versus time curve from zero to the last data point above the lower limit of quantitation [AUC(0-tlast)], if AUC cannot be estimated in all subjects. In subjects with normal and moderately reduced renal function.
    date_rangeTime Frame:
    -1hour (h), 30minutes (min), 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1day (d), 2d, 3d, 4d, 7d, 10d, 14d
  • Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of BAY1002670
    In subjects with normal and moderately reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d

Secondary Outcome

  • Number of participants with adverse events
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    Up to 6 weeks
  • AUC
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • unbound AUC (AUCu)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Cmax
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Unbound Cmax (Cmax,u)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Apparent oral clearance (CL/F)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Unbound CL/F (CLu/F)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Half-life associated with the terminal slope (t1/2)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Renal clearance (CLR)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d
  • Fraction of free (unbound) drug in plasma (fu)
    In subjects with normal, moderately, and severely reduced renal function.
    date_rangeTime Frame:
    -1h, 30min, 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 12h ,16h, 1d, 2d, 3d, 4d, 7d, 10d, 14d

Trial design

An open-label, single-dose study to evaluate the pharmacokinetics and safety of vilaprisan in subjects with decreased renal function in comparison with matched subjects with normal renal function
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Other
Allocation
Non-randomized
Blinding
N/A
Assignment
Parallel Assignment
Trial Arms
3